Skip to content

Two Treatment Regimens of Cocamide DEA Lotion for Head Lice

A Randomised, Parallel Group Clinical Trial to Assess the Efficacy, Safety and Acceptability of a Surfactant Based Lotion in the Treatment of Head Louse Infection.

Status
Terminated
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02499549
Enrollment
112
Registered
2015-07-16
Start date
1999-10-31
Completion date
1999-12-31
Last updated
2015-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head Louse Infestation, Pediculosis

Brief summary

To assess the efficacy and safety of 10% Cocamide DEA using two treatment regimens in the eradication of head lice. To assess the ability of each treatment regimen to kill all viable ova and to assess patient acceptability of the product in use

Detailed description

A previous study found that a formulation of 10% cocamide diethanolamine (DEA) aqueous lotion showed some efficacy to eliminate head louse infestation but that the treatment regimen was inadequate to kill all lice or louse eggs. This study has been designed to compare two different application regimens that have been shown effective in vitro. A planned total of 120 patients who, following examination, are found to suffer from active head lice infestation will be recruited to the trial. The patient will be treated with 10% cocamide DEA lotion using the appropriate treatment regimen according to the randomization code from a pre-prepared listing in balanced blocks of 12. Group 1: 10% cocamide DEA is applied directly to dry hair, the excess water evaporated off using a hair dryer and is then left for 8 hour/overnight before washing off with clean water. Group 2: 10% cocamide DEA is applied directly to dry hair, the excess water evaporated off using a hair dryer and is then left for 2 hours before washing off with clean water. A follow up treatment is given after 7 days. Treatments will be applied by experienced investigators throughout the study. Assessments will be made by other investigators unaware of the treatment regimen used. After treatment (day 0), follow up assessments will be performed on days 4, 8,11 then again at day 14 after which they will leave the study. Any adverse events or side effects from the treatments will be monitored during the study.

Interventions

10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only

Sponsors

Riemann a/s
CollaboratorUNKNOWN
Medical Entomology Centre
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male and female patients over the age of 4 who are found to have a head louse infection. * Patients who give written informed consent and, if the patient is under 16 years of age, whose guardian gives written informed consent to participate in the study. * Available for the duration of study i.e. 15 days.

Exclusion criteria

* Patients with a known sensitivity to paraben preservatives. * Patients who have been treated with other head lice products within the last 2 weeks. * Patients who have undergone a course of antibiotic treatment within the last 4 weeks. * Patients who have any persistent skin disorder of the scalp (i.e. eczema, chronic dermatitis, psoriasis). * Patients whose hair has been bleached, colour treated or permed within the last 4 weeks. * Patients who have participated in another clinical trial within 1 month prior to entry to this study. * Patients who have already participated in this clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Successful elimination of infestation14 daysNo evidence of active head lice infestation 14 days after enrolment

Secondary

MeasureTime frameDescription
Number of participants with treatment related adverse events as a measure of safety14 daysNo treatment related adverse events following treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026